一分钟看懂
这是一项关于非小细胞肺癌的II 期 / III 期研究，登记的药物或干预包括Telisotuzumab Adizutecan；Standard of Care；Osimertinib，当前状态为招募中。登记地点显示中国广州、南昌、上海、乌鲁木齐有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Telisotuzumab Adizutecan；Standard of Care；Osimertinib · II 期 / III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录5项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出5项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Guangdong Provincial People's Hospital /ID# 277631 · 广州
- The First Affiliated Hospital of Nanchang University - Xianghu Campus /ID# 277491 · 南昌
- Shanghai Pulmonary Hospital /ID# 277488 · 上海
- Xinjiang Medical University Cancer Hospital - Urumqi /ID# 277638 · 乌鲁木齐
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Histologically or cytologically confirmed diagnosis of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R mutation.
- * Provide recently obtained tumor tissue during Screening for c-Met immunohistochemistry (IHC) testing (and study stratification in Phase 2). If recently obtained tumor tissue is not available, archived tumor tissue is also acceptable.
- * Received one prior third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy in the adjuvant, locally advanced, or metastatic setting, either as monotherapy or in combination with other agents, and experienced documented radiographic disease progression on or after therapy for the most recent regimen administered prior to study entry. Participant who has received prior third-generation EGFR TKI therapy in the adjuvant setting must have progressed while on treatment.
- * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
- * At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, that has not been previously irradiated.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07155187；登记信息更新于 2026-10-05；本站同步于 2026-10-08，中国中心当前名额未经人工确认。